EUVIMEDEUVIMED entdecken
Open Access

Albumin‑bilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis

Fenghui Li, Tao Wang, Jing Liang, Baoxin Qian, Fei Tang, Yanying Gao, Jiayu Lv

Experimental and Therapeutic Medicine · 11.09.2023 · 26 (5)

DOI: 10.3892/etm.2023.12200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 11.09.2023. Verfasst von Fenghui Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extra-Corporeal Life Support for Crit…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rebleeding following endoscopic treatment in patients with cirrhosis is a serious life-threatening complication. In the present study, a novel, reliable and non-invasive score for prediction of rebleeding following endoscopic therapy for esophagogastric variceal bleeding (EGVB) was developed. The present retrospective study recruited cirrhotic patients with EGVB (n=596) who underwent endoscopic therapy. Patients hospitalized from January 2015 to January 2020 were grouped into a training (n=437) cohort to develop the new score and those hospitalized from February 2020 to February 2022 were grouped into a validation (n=159) cohort to validate the score. The international normalized ratio (INR) and albumin-bilirubin (ALBI) grade were used to develop the INR-ALBI (IALBI) score to predict risk of rebleeding. In the training cohort, the prognostic performance of the IALBI score and other ALBI-associated scores (modified ALBI, platelet-ALBI and ALBI-fibrosis-4) at 1, 3 and 12 months was assessed using receiver operating characteristic (ROC) curve and Kaplan-Meier analysis. At each time point, most areas under the ROC curve of IALBI were higher than those of other ALBI-associated scores, particularly for prediction of early rebleeding. At 1 month, the rebleeding rates of patients with IALBI grade 2 and 3 were ~10.0- and 19.5-times higher than those of patients with grade 1, respectively. The negative predictive value (NPV) of IALBI for the training and validation cohort at 1 month was 100.0 and 97.8%, respectively. For viral and non-viral patients in the training cohort, IALBI showed good predictive ability and NPV for early rebleeding. The IALBI grading system successfully assessed rebleeding, particularly early rebleeding, in cirrhotic patients with EGVB following endoscopic therapy IALBI grade 1, predicted low risk of rebleeding and may not require endoscopic treatment again in the short-term.

Schlagwörter

Stichwörter der Autor:innen

albumin-bilirubinesophagogastric varicesfibrosis-4international normalized ratioliver cirrhosismodified ALBIplatelet ALBIrebleeding

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin Key Laboratory of Extra-Corporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center,…

Zitieren

APA

Li, F., Wang, T., Liang, J., Qian, B., Tang, F., Gao, Y., & Lv, J. (2023). Albumin‑bilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis. Experimental and Therapeutic Medicine, 26(5). https://doi.org/10.3892/etm.2023.12200

Vancouver

Li F, Wang T, Liang J, Qian B, Tang F, Gao Y, et al. Albumin‑bilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis. Experimental and Therapeutic Medicine. 2023;26(5). doi:10.3892/etm.2023.12200

BibTeX
@article{Li2023,
  author = {Li, Fenghui and Wang, Tao and Liang, Jing and Qian, Baoxin and Tang, Fei and Gao, Yanying and Lv, Jiayu},
  title = {Albumin‑bilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis},
  journal = {Experimental and Therapeutic Medicine},
  year = {2023},
  volume = {26},
  number = {5},
  doi = {10.3892/etm.2023.12200}
}
Kostenlos starten →